Urinary excretion of l-carnitine and its short-chain acetyl-l-carnitine in patients undergoing carboplatin treatment

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 1, 2007, Pages 19-26

  Mancinelli, Angelo ^a   D'Iddio, S ^a   Bisonni, R ^b   Graziano, F ^c   Lippe, P ^d   Calvani, M ^a  

^a Scientific Department   (Italy)

^b Hospital of Fermo   (Italy)

^c Hospital of Urbino   (Italy)

^d Fano Hospital   (Italy)

Author keywords

Acetyl L carnitine; Carboplatin; L Carnitine; Renal clearance; Urinary excretion

Indexed keywords

CARBOPLATIN; CARNITINE; CREATININE; DOCETAXEL; GLUCOSE; LEVACECARNINE; NAVELBINE; NITROGEN; PACLITAXEL; PHOSPHATE; UREA;

ADULT; AGED; AMINO ACID BLOOD LEVEL; AMINO ACID URINE LEVEL; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFICACY; FEMALE; FLUOROMETRY; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY CLEARANCE; KIDNEY FUNCTION; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; UREA NITROGEN BLOOD LEVEL; URINARY EXCRETION;

ACETYLCARNITINE; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARNITINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CREATININE; FEMALE; GLUCOSE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; PHOSPHATES; TAXOIDS; UREA; VINBLASTINE;

EID: 34247385833     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0341-3     Document Type: Article

References (34)

1. Baker SD, Sparreboom A, Verweij J (2006) Clinical pharmacokinetics of docetaxel: recent developments. Clin Pharmacokinet 45:235-252
2. Bieber LL (1988) Carnitine. Annu Rev Biochem 57:261-283
3. Boulikas T, Vougiouka M (2004) Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review). Oncol Rep 11:559-595
4. Bowyer BA, Fleming CR, Haymond MW, Miles JM (1989) L-carnitine: effect of intravenous administration on fuel homeostasis in normal subjects and home-parenteral-nutrition patients with low plasma carnitine concentrations. Am J Clin Nutr 49:618-623
5. Cockcroft D, Gault M (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
6. Cruciani RA, Dvorkin E, Homel P, Culliney B, Malamud S, Shaiova L, Fleishman S, Lapin J, Klein E, Lesage P, Portenoy R, Esteban-Cruciani N (2004) L-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency. Ann N Y Acad Sci 1033:168-176
7. Dodson WL, Sachan DS, Krauss S, Hanna W (1989) Alterations of serum and urinary carnitine profiles in cancer patients: hypothesis of possible significance. J Am Coll Nutr 8:133-142
8. Engel AG, Rebouche CJ, Wilson DM, Glascow AM, Romshe CA, Cruse RP (1981) Primary systemic carnitine deficiency. II. Renal handling of carnitine. Neurology 31:819-825
9. Frohlich J, Seccombe DW, Hahn P, Dodek P, Hynie I (1978) Effect of fasting on free and esterified carnitine levels in human serum and urine: correlation with serum levels of free fatty acids and β-hydroxybutyrate. Metabolism 27:555-561
10. Ganapathy ME, Huang W, Rajan P, Carter AL, Sugawara M, Iseki K, Leibach FH, Ganapathy V (2000) β-Lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem 275:1699-1707
11. Graziano F, Bisonni R, Catalano V, Silva R, Rovinati S, Mencarini E, Ferraro B, Canestrai F, Balzelli AM, De Gaetano A, Giordani P, Testa E, Lai V (2002) Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anemic cancer patients. Br J Cancer 86:1854-1857
12. Gregory RK, Smith IE (2000) Vinorelbine: a clinical review. Br J Cancer 82:1907-1913
13. Heuberger W, Berardi S, Jacky E, Pey P, Krahenbuhl S (1998) Increased urinary excretion of carnitine in patients treated with cisplatin. Eur J Clin Pharmacol 54:503-508
14. Hoppel CL, Genuth SM (1980) Carnitine metabolism in normal-weight and obese human subjects during fasting. Am J Physiol Endocrinol Metab 238:E409-E415
15. Koepsell H (2004) Polyspecific organic cation transporters: their functions and interactions with drugs. Trends Pharmacol Sci 25:375-381
16. Longo A, Bruno G, Curti S, Mancinelli A, Miotto G (1996) Determination of L-carnitine, acetyl-L-carnitine and propionyl-L- carnitine in human plasma by high-performance liquid chromatography after pre-column derivatization with 1-aminoanthracene. J Chromatogr 686:129-139
17. Mancinelli A, Longo A, Shanahan K, Evans AM (1995) Disposition of L-carnitine and acetyl-L-carnitine in the isolated perfused rat kidney. J Pharmacol Exp Ther 274:1122-1128
18. Marthaler NP, Visarius T, Kupfer A, Lauterburg BH (1999) Increased urinary losses of carnitine during ifosfamide chemotherapy. Cancer Chemother Pharmacol 44:170-172
19. Marzo A, Arrigoni-Martelli E, Urso R, Rocchetti M, Rizza V, Kelly JG (1989) Metabolism and disposition of intravenously administered acetyl-L-carnitine in healthy volunteers. Eur J Clin Pharmacol 37:59-63
20. Melegh B, Kerner J, Bieber LL (1987) Pivampicillin-promoted excretion of pivaloylcarnitine in humans. Biochem Pharmacol 36:3405-3409
21. Natali A, Santoro D, Brandi LS, Faraffiana D, Ciociaro D, Pecori N, Buzzigoli G, Ferrannini E (1993) Effects of acute hypercarnitinemia during increased fatty substrate oxidation in man. Metabolism 42:594-600
22. Nezu J, Tamai I, Oku A, Ohashi R, Yabuuchi H, Hashimoto N, Nikaido H, Sai Y, Koizumi A, Shoji Y, Takada G, Matsuishi T, Yoshino M, Kato H, Ohura T, Tsujimoto G, Hayakawa J, Shimane M, Tsuji A (1999) Primary systemic carnitine deficiency is caused by mutation in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet 21:91-94
23. Noble S, Goa KL(1999) Adefovir dipivoxil. Drugs 58:479-487
24. +-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther 291:778-784
25. Rebouche CJ, Seim H (1998) Carnitine metabolism and its regulation in microorganisms and mammals. Annu Rev Nutr 18:39-61
26. Rossle C, Pichard C, Roulet M, Bergstrom F, Furst P (1989) Muscle carnitine pools in cancer patients. Clin Nutr 8:341-346
27. Rowinsky EK (1997) The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 48:353-374
28. Tamai I, Ohashi R, Nezu J, Yabuuchi H, Oku A, Shimane M, Sai Y, Tsuji A (1998) Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem 273:20378-20382
29. Tune BM, Hsu CY (1994) Toxicity of cephaloridine to carnitine transport and fatty acid metabolism in rabbit renal cortical mitochondria: structure-activity relationships. J Pharmacol Exp Ther 270:873-880
30. Van der Vijgh WJF (1991) Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 21:242-261
31. Vinci E, Rampello E, Zanoli L, Oreste G, Pistone G, Malaguerra M (2005) Serum carnitine levels in patients with tumoral cachexia. Eur J Int Med 16:419-442
32. +-carnitine co-transporter hOCTN2. Am J Physiol Renal Physiol 279:F584-F591
33. Yaris N, Akyuz C (2002) Serum carnitine levels of pediatric patients. Pediatr Hematol Oncol 19:1-8
34. Yaris N, Ceviz N, Coskun T, Akyuz C, Buyukpamukcu M (2002) Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity. J Exp Clin Cancer Res 21:165-170